Get the Stockscreener App
63.63
0.89%
-0.57
After Hours:
63.00
-0.63
-0.99%
Cytokinetics Inc stock is traded at $63.63, with a volume of 1.75M.
It is down -0.89% in the last 24 hours and down -4.75% over the past month.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$64.20
Open:
$63.73
24h Volume:
1.75M
Relative Volume:
0.92
Market Cap:
$7.84B
Revenue:
$18.47M
Net Income/Loss:
$-589.53M
P/E Ratio:
-12.10
EPS:
-5.26
Net Cash Flow:
$-399.80M
1W Performance:
+2.18%
1M Performance:
-4.75%
6M Performance:
+19.34%
1Y Performance:
+43.31%
1-Day Range:
$61.46
$63.83
1-Week Range:
$59.63
$64.68
52-Week Range:
$29.31
$70.98
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
63.63 | 7.91B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.38 | 126.81B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
774.66 | 81.62B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.09 | 45.97B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.43 | 42.76B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
298.91 | 33.88B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Overweight |
| Dec-18-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-30-25 | Resumed | Raymond James | Mkt Perform |
| Apr-24-25 | Initiated | Barclays | Overweight |
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Cytokinetics at Barclays Conference: Strategic Growth and Global Ambitions - Investing.com
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Leerink Maintains Outperform for Cytokinetics, Incorporated (CYTK) March 2026 - Meyka
Robert Blum Sells 7,931 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Cytokinetics (NASDAQ:CYTK) EVP Sells $156,779.04 in Stock - MarketBeat
Cytokinetics Leaders Gained $16 Million as Insiders, Suit Says - Bloomberg Law News
Cytokinetics at The Citizens Life Sciences Conference: Myqorzo’s Market Potential - Investing.com Canada
Leerink reiterates Cytokinetics stock rating on launch confidence By Investing.com - Investing.com Canada
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market - Yahoo Finance
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market - The Motley Fool
Cytokinetics at Leerink Global Healthcare Conference: Strategic Growth in Cardiology - Investing.com Canada
UBS Maintains Neutral on CYTK, Cytokinetics, Incorporated March 2026 - Meyka
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Leerink Partners Global Biopharma Conference 2026: TEVA, CYTK, IMRX, TNYA And More Set To Present - RTTNews
Rhenman & Partners Asset Management AB Raises Stake in Cytokinetics, Incorporated $CYTK - MarketBeat
Knott David M Jr Purchases Shares of 30,000 Cytokinetics, Incorporated $CYTK - MarketBeat
GW&K Investment Management LLC Takes $9.93 Million Position in Cytokinetics, Incorporated $CYTK - MarketBeat
GABELLI & Co INVESTMENT ADVISERS INC. Makes New $2.06 Million Investment in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics (CYTK) Analyst Rating: UBS Raises Price Target to $69.00 | CYTK Stock News - GuruFocus
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Ascendis Pharma (ASND) and Avalo Therapeutics (AVTX) - The Globe and Mail
Callos, Cytokinetics EVP, sells $1.6 million in CYTK stock - Investing.com UK
Callos, Cytokinetics EVP, sells $1.6 million in CYTK stock By Investing.com - Investing.com Canada
Cytokinetics: From Aficamten Trials to MYQORZO Launch—A High-Stakes Race in the HCM Market! - Smartkarma
Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 26,000 Shares - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Investors to Inquire about Securities Investigation - ACCESS Newswire
Segall Bryant & Hamill LLC Boosts Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Royce & Associates LP Invests $5.50 Million in Cytokinetics, Incorporated $CYTK - MarketBeat
Legato Capital Management LLC Takes Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Fisher Asset Management LLC Raises Stock Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics Is Priced For A Big MYQORZO Launch - Finimize
Rafferty Asset Management LLC Has $5.72 Million Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
CYTK Should I Buy - Intellectia AI
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Cytokinetics Wins Dual MYQORZO Approvals But Faces Execution And Loss Risks - simplywall.st
Insider Sell: B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
EVP at Cytokinetics (NASDAQ: CYTK) sells 886 shares after option exercise - Stock Titan
[144] CYTOKINETICS INC SEC Filing - Stock Titan
Director Lynne Parshall trims Cytokinetics (CYTK) stake in sale - Stock Titan
Cytokinetics to Participate in March Investor Conferences - The Manila Times
March investor fireside chats: Cytokinetics to webcast - Stock Titan
Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech With A 46.52% Potential Upside - DirectorsTalk Interviews
Cytokinetics, Incorporated $CYTK Stock Position Raised by Handelsbanken Fonder AB - MarketBeat
CYTK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Assessing Cytokinetics (CYTK) Valuation After Recent Share Price Weakness And Aficamten Expectations - Yahoo Finance
A Look At Cytokinetics (CYTK) Valuation After Recent Share Price Pullback - simplywall.st
Monashee Investment Management LLC Buys Shares of 100,000 Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics (HAM:KK3A) Total Receivables : €1.54 Mil (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) Inventories, Raw Materials & Components : €0.00 Mil (As of Sep. 2025) - GuruFocus
TD Asset Management Inc Raises Stake in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics (HAM:KK3A) Inventories, Inventories Adjustments : €0.00 Mil (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) YoY Rev. per Sh. Growth : 250.00% (As of Sep. 2025) - GuruFocus
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.57%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):